Open Access<p>ACEIs and ARBs and Their Correlation with COVID-19: A Review</p>
Author(s) -
Awgichew Shewasinad Yehualashet,
Teshome Fentik Belachew
Publication year - 2020
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s264882
Subject(s) - covid-19 , medicine , diabetes mellitus , heart failure , disease , cardiology , virology , endocrinology , infectious disease (medical specialty) , outbreak
Although some animal studies suggested that the use of ACEIs/ARBs could contribute for the prevention and treatment of the effects of the COVID-19 infection, there are also contradictory scenarios indicating that their use may exacerbate the deleterious conditions of the infection. As a result of the paradoxical issue of using ACEIs/ARBs during COVID-19, it is still an area requiring extended investigation to prove. Additionally, a trial evidence of their efficacy and the possible benefit risk analysis of these conventional drugs during COVID-19 in connection with other comorbidities like hypertension, heart failure, and renal disease associated with diabetes should also be addressed.